The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

• Status: Recruiting
• Trial end date: 2022-12-20
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers. Ninety patients will be recruited and they will be randomly distributed in three groups. The first group will receive treatment with Cannabidiol 5%, the second group will receive treatment with Vivimind and the third group will not receive any treatment. The three groups will be compared by using an extensive neuropsychological examination and biomarkers' results from cerebrospinal fluid and blood

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aristotle University Of Thessaloniki
• Collaborator: Greek Alzheimer's Association and Related Disorders
• Treatments: Cannabidiol; Epidiolex; Tramiprosate

Criteria

Inclusion Criteria:

• Diagnosis of Mild Cognitive Impairment

• Carry APOE ε4 gene

Exclusion Criteria:

• Diagnosis of Dementia

• Patients who receive medication for memory or depression

• Patients who do not carry APOE ε4 gene